Investors Relations - PerioTrap Pharmaceuticals

Investors Relations

Pipeline

Publicly funded programs

KMUi-Biomedizin-1: Entwicklung und präklinische Qualifizierung neuartiger Parodontitis-Therapeutika für die klinische Anwendung (ParoPaste) - Erforschung und präklinische Qualifizierung neuartiger Parodontitis-Therapeutika in Proof-of-Concept Modellen und regulatorische Vorbereitung für die klinische Anwendung

Alternative metal binding groups in drugs for the treatment of periodontitis - AMePA

Controlled release drug delivery systems of innovative and selective drug molecules for the treatment of bacterial infectious diseases of the periodontum – ParoStop

Profiling inhibitors of bacterial glutaminyl cyclases as drug prototypes of novel periodontal therapeutics - PInParo

Awards & Investments By

Awards

Investments By

Publications

2019

Extrudates of lipophilic tetracycline complexes: A new option for periodontitis therapy

https://www.sciencedirect.com/science/
article/pii/S0378517319308397

https://www.sciencedirect.com/science/article/pii/S0378517319308397

2020

Controlled release minocycline-lipid-complex extrudates for the therapy of periodontitis with enhanced flexibility

https://www.sciencedirect.com/science/article/pii/S0378517320305627

https://www.sciencedirect.com/science/
article/pii/S0378517320305627

2020

In Vitro Evaluation of Antimicrobial Activity of Minocycline Formulations for Topical Application in Periodontal Therapy

https://www.mdpi.com/1999-4923/12/4/352

2021

Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis

https://www.sciencedirect.com/science/article/pii/S0021925821000302

https://www.sciencedirect.com/science/
article/pii/S0021925821000302

2021

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase

https://www.mdpi.com/1372046

PerioTrap Pharmaceuticals GmbH